Phosphorylation of RAF kinase dimers drives conformational changes that facilitate transactivation by Jambrina, Pablo G. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/anie.201509272
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Jambrina, P. G., Rauch, N., Pilkington, R., Rybakova, K., Nguyen, L. K., Kholodenko, B. N., ... Rosta, E. (2016).
Phosphorylation of RAF kinase dimers drives conformational changes that facilitate transactivation.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 55(3), 983-986. 10.1002/anie.201509272
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
German Edition: DOI: 10.1002/ange.201509272Signaling Proteins
International Edition: DOI: 10.1002/anie.201509272
Phosphorylation of RAF Kinase Dimers Drives Conformational
Changes that Facilitate Transactivation
Pablo G. Jambrina+, Nora Rauch+, Ruth Pilkington, Katja Rybakova, Lan K. Nguyen,
Boris N. Kholodenko, Nicolae-Viorel Buchete, Walter Kolch,* and Edina Rosta*
Abstract: RAF kinases are key players in the MAPK signaling
pathway and are important targets for personalized cancer
therapy. RAF dimerization is part of the physiological
activation mechanism, together with phosphorylation, and is
known to convey resistance to RAF inhibitors. Herein,
molecular dynamics simulations are used to show that
phosphorylation of a key N-terminal acidic (NtA) motif
facilitates RAF dimerization by introducing several interpro-
tomer salt bridges between the aC-helix and charged residues
upstream of the NtA motif. Additionally, we show that the R-
spine of RAF interacts with a conserved Trp residue in the
vicinity of the NtA motif, connecting the active sites of two
protomers and thereby modulating the cooperative interactions
in the RAF dimer. Our findings provide a first structure-based
mechanism for the auto-transactivation of RAF and could be
generally applicable to other kinases, opening new pathways
for overcoming dimerization-related drug resistance.
RAF kinases connect the Ras GTPase to activation of the
MEK-ERK pathway. This pathway regulates many funda-
mental cellular functions, including cell proliferation, and is
dysregulated in approximately 50% of human cancers.[1] This
pathway has thus been a key focus in cancer drug develop-
ment. A recent breakthrough came with the BRAF inhibitor
vemurafenib, which achieved high response rates in BRAF-
mutated metastatic melanoma.[2] Interestingly, BRAF inhib-
ition in RAS-mutated tumors induces paradoxical ERK
activation and tumor progression owing to the formation of
RAF dimers.[3] RAF dimerization is also a major mechanism
of acquired clinical resistance to RAF inhibitors.[4] Owing to
its important clinical implications, RAF dimerization has
attracted enormous interest. RAF homo- and heterodimers
show significantly higher kinase activity than monomers, and
it has been shown that physiological RAF activation involves
dimerization.[1,5] Dimer activity remains high even when one
protomer (denoted as the activator) is kinase-dead or
inhibited, owing to allosteric transactivation of its binding
partner (the receiver).[1,5] Recent data indicate that the N-
terminal acidic (NtA) motif[6] is essential for the allosteric
activation of RAF dimers.[7] This region is located just
upstream of the kinase domain and mediates physiological
activation. In RAF1, phosphorylation of the corresponding
sequence SSYY (residues 338–341) is induced during RAF1
activation.[6b,8] In BRAF (residues 446–449, sequence SSDD),
the activating site S446 is constitutively phosphorylated and
the tyrosines are replaced by negatively charged aspartates.
This configuration of the NtA motif primes BRAF for
activation, which may explain why single mutations of
BRAF, such as V600E in the activation loop, can cause full
activation and drive cancer, while RAF1 mutations are rare in
cancer.[9] There is no consensus on which kinase phosphor-
ylates the NtA motif in vivo, since several kinases, including
RAF1 itself, have been reported to be able to do this.[1, 10] As
shown by mutagenesis studies,[7] the NtA motif in the
activator is required for transactivation of the receiver in
RAF dimers. However, no structural evidence is available to
explain this allosteric activation process, since all RAF crystal
structures lack the NtA motif.
Based on recently available crystallographic data for RAF
(e.g., PDB entries 4E26[11] and 3OMV[3b]) we modeled RAF
homo- and heterodimers that include the NtA region and
correspond to the smallest subset of residues present at the
N terminus of the kinase domain in constitutively dimerized,
drug resistant splice variants[4] (Figure 1a). By using atomistic
molecular dynamics (MD) simulations of kinase dimers,[12] we
also investigated the role of phosphorylation, which is
biochemically well documented but has eluded detailed
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structural studies. The computational modeling approach and
the parameters used are described in the Methods section of
the Supporting Information and summarized in Table S1.
Phosphorylation of the NtA motif generates several salt
bridges that extend and stabilize the binding interface
between two BRAF protomers (Figure 1b). Intriguingly,
these salt bridges are primarily interprotomer salt bridges,
which are formed between the NtA motif and positive
residues located either upstream of the NtA motif or at the
C-terminal end of the aC-helix, the orientation of which plays
an important role in kinase activation.[12a, 13]
We note that all of the residues that form interprotomer
salt bridges with phosphorylated residues of the NtA motif
are conserved in the three RAF isoforms, but not in other
kinases (Table S2 in the Supporting Information). Remark-
ably, the C-terminal end of the aC-helix is neutral in most
kinases, whereas in RAFs it carries a +3 charge. Moreover,
mutations of these charged residues impair kinase activity[14]
and affect RAF homo- and heterodimerization.[3b,14, 15] Since
RAF kinases dimerize via the C-terminal end of the aC-helix,
the accumulation of six positive charges at the dimerization
interface enables interaction with the highly negatively
charged NtA motif (specific to RAF), thereby promoting
the dimerization. In fact, we estimate that NtA phosphor-
ylation constitutes almost half of the interaction potential
energy between the BRAF protomers (Figure 2a and
Table S1), predominantly by enhancing electrostatic interac-
tions. In particular, we identified two conserved Arg residues,
R443 (R336) at the NtA region and R506 (R398) close to the
aC-helix in BRAF (RAF1), that participate in the intermo-
lecular salt bridges. R506 (R398) has been reported previ-
ously to play a role in dimerization,[14] and here we confirmed
the relevance of R443 (R336) experimentally by co-immu-
noprecipitation, demonstrating a reduced dimerization pro-
pensity of R!A mutants (Figure 2b). The differences
between BRAF and RAF1 in terms of their cellular phos-
phorylation states (i.e., BRAF is constitutively phosphory-
lated whereas RAF1 activation requires additional input[6b])
and the exact sequences of the NtA motifs (Figure 1b, and
Figures S1–S3 in the Supporting Information) explain the
significant differences between the activities of BRAF and
RAF1 homo- and heterodimers.[5c]
Our simulations also reveal that the phosphorylated NtA
motif is connected to the active site via the R-spine[16]
(Figure 3a). This conserved hydrophobic structure connects
four residues from critical sites in the kinase monomer,[16a,17]
including the active site. The R-spine is anchored to the aF-
Figure 1. a) Structure of the phosphorylated BRAF homodimer with
bound ATP (ATP-PBRAF), obtained from MD simulations. Key struc-
tural elements are highlighted: the NtA motif, the R-spine, and the aC
and aF helices. b) Interactions of the NtA motif within the phosphory-
lated BRAF homodimer and the phosphorylated BRAF–RAF1 heterodi-
mer. The newly formed interchain ion pairs are highlighted for
protomers A and B (cyan and yellow, respectively). See also Figur-
es S1–S3.
Figure 2. a) Average interaction potential energy (see the Supporting
Information for details) between protomer A and protomer B for BRAF
homo- and heterodimers. Only the last 75% segment of the simulation
was considered. The results for the phosphorylated dimers include
contributions for three different trajectories. For the phosphorylated
BRAF homodimers, we show results where i) all the activating regu-
latory residues (S446, S579, T599 and S602) are phosphorylated
(pBRAF), and ii) only the NtA motif was phosphorylated (pS446 BRAF).
b) BRAF R443A and RAF1 R336A mutants show reduced heterodimeri-
zation. Mutants of BRAF and RAF1 were transiently overexpressed in
HEK293T cells. Dimerization was analyzed by co-immunoprecipitation
(IP) from EGF-stimulated cells. V5=V5-tag, FLAG=FLAG-tag, TL= to-
tal lysate, *p=0.0192, **p=0.0058, n.s.=not significant (p=0.1108).
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helix via a hydrogen bond between a carboxylate group at the
N-terminal end of the aF-helix and the backbone of the HRD
motif.[16b] An assembled R-spine indicates active kinase
conformations, while a broken R-spine correlates with
inactive kinase conformations.[16]
Previous experiments showed that mutation of a con-
served Trp residue (W450 for BRAF, Table S2) impedes
transactivation and impairs the dimerization of BRAF.[7] We
observed that W450 extends the R-spine by forming stacking
interactions with the fourth residue (R4, Figure 3a).
Although W450 is highly conserved in most kinases
(Table S2), the interaction between this Trp and the R4
residue of the R-Spine is not always observed. R4 is aliphatic
in about 80% of the kinases, including PKA. In PKA, CDK2,
and p38 structures, the R-spine and the corresponding Trp do
not interact. Although this Trp is not conserved in EGFR,
crystal structures show that its functional equivalent lysine
(L680)[18] also interacts with the R-spine. Remarkably,
mutation of L680 destabilizes the EGFR dimer in the active
complex and impedes kinase activity.[18] We observed that the
NtA motif together with W450 extends the dimerization
interface, thereby connecting the R-spines and thus the
distant active sites of the two protomers. For PKA, aliphatic-
to-aromatic mutation of R4 gives normal levels of catalytic
activity.[19] This is also the case for BRAF F516A and F516L
mutations, which maintain the catalytic activity (Figure 3b)
because they preserve the integrity of the R-spine within the
monomer. However, we found that these BRAF mutants are
unable to transactivate RAF1 in the heterodimer (Figure 3c).
These results provide a first structure-based explanation for
the transactivation mechanism of RAF dimers following NtA
motif phosphorylation.
Importantly, our results indicate phosphorylation-induced
large-scale structural changes in RAF dimers, whereas the
unphosphorylated dimers remain structurally similar to their
starting structures, in agreement with the crystallographic
structures. Only when all phosphorylated residues, including
the two activation-loop residues near V600, are present in the
simulated system, we observe large changes between the
universally conserved HRD and DFG motifs (Figure 4).
These changes provide insight into the structural flexibility
Figure 3. a) R-spine of the two protomers of ATP-PBRAF. R1–R4
denotes the four residues that form the R-spine (H574, F595, L505,
and F516 for BRAF). The conserved Trp (W450 for BRAF) extends the
R-spine, connecting it with the dimerization interface. b) F516A
mutation does not affect the activity of BRAF. HEK293T cells were
transfected with FLAG-tagged BRAF mutants (as indicated). Lysates
were collected the next day from growing cells. c) F516 is required for
transactivation activity of kinase-dead BRAF. HEK293T cells were
transiently transfected with FLAG-FKBP-tagged BRAF and V5-FRB-
tagged RAF1. Heterodimer formation in serum-starved cells was
induced by addition of 500 nm A/C heterodimerizer for 1 hour. Total
lysates were collected and analyzed. Substitution of F516 in kinase-
dead BRAF K483M resulted in reduced ERK activation by RAF hetero-
dimers.
Figure 4. a) Free energies along the D575–D593 distance. a) Simulations
M1 and M2 (without phosphorylated residues). b) Simulations M3a, M5a,
and M8 (with phosphorylation taken into account). c,d) Snapshots of the
MD simulation structures at the beginning (c), and at the end (d) of the
simulation trajectory M3a, highlighting the D575–D593 distance and the
corresponding detachment of the R-spine from the anchoring aF-helix.
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present in the kinase domains, and could provide a structural
explanation for recent observations on transactivation.[7]
Remarkably, these changes involve structural elements that
are connected via the R-spine and/or the NtA motif, and they
typically occur in only one of the protomers, thereby giving
rise to asymmetry in the dimer. Interestingly, only structures
that include vemurafenib or closely related inhibitors (PDB
entries 3OG7,[20] 4FK3,[21] and 3C4C[21]) present asymmetrical
dimers, which have been proposed as a general mechanism for
the allosteric modulation of kinase activity.[22] Our protomer
structures differ from these inactive crystal structures, since
the presence of ATP enhances the stability of the salt bridge
between K483 and E501, which is absent in the vemurafenib-
bound structures. Therefore, our protomer structures could be
useful leads for the development of drugs that avoid the
paradoxical kinase activation resulting from drug-induced
RAF dimerization.
In summary, our results show that phosphorylation of the
NtA motif promotes dimerization through several interpro-
tomer salt bridges formed between the NtA motif of one of
the protomers and the positively charged C-terminal end of
the aC-helix of the other protomer. They further reveal the
importance of the conserved tryptophan residue located at
the N-terminal end of the kinase domain (W450 for BRAF),
which plays a crucial role by connecting the R-spines of the
two protomers. This suggests a cooperative interprotomer
interaction that is mediated by salt bridges involving the
phosphorylated NtA motif. The direct interaction of the R-
spines via W450 explains why mutation of W450 abolishes the
transactivation of RAF dimers.[7] More importantly, this also
explains how the phosphorylated dimers undergo significant
conformational changes. These changes involve detachment
of the R-spine from the anchoring aF-helix, and significant
changes to the residue pair distances between the HRD and
DFG motifs. The asymmetric transactivation mechanism of
RAF kinases also provides a structural basis for understand-
ing the paradoxical activation caused by type I and type IIB
inhibitors.[23]
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